Biohaven Faces Partial FDA Clinical Hold on Epilepsy Trials

Biohaven Ltd, a pharmaceutical company, faced a significant setback on September 10, 2026, when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials. This development sent Biohaven's stock price plummeting by nearly 15%, or $2.21, representing a 14.73% drop. The news sent shockwaves through the market, causing investors to lose substantial amounts of money.

In a statement, Biohaven disclosed that the FDA had requested an update on ongoing nonclinical studies and rodent testing. The agency cited a lack of sufficient information regarding a specific metabolite as the reason for the hold. Despite the partial hold, the company assured that dosing would continue for patients already enrolled in the BHV-7000 program.

The setback came just 15 days after Biohaven announced a significant milestone, a global licensing agreement with SK Biopharmaceuticals. The deal, valued at up to $795 million, was intended to accelerate the development and commercialization of opakalim, the drug at the center of the current controversy. However, the partial clinical hold has cast a shadow over the company's progress.

Investors who purchased Biohaven shares and suffered losses are encouraged to contact Joseph E. Levi, Esq., of Levi & Korsinsky LLP, for a no-cost, no-obligation evaluation of their potential recovery. Levi & Korsinsky, a nationally recognized securities litigation firm, has a track record of securing millions of dollars for aggrieved shareholders.

Levi & Korsinsky has been investigating potential securities claims on behalf of Biohaven investors. The firm, which has been ranked in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years, is well-equipped to handle complex securities litigation. Investors are advised to gather their brokerage records, showing purchase dates, share quantities, and prices paid, to facilitate the evaluation process.

The partial clinical hold on the BHV-7000/opakalim epilepsy trials has left many investors questioning the future of the drug's development. The hold has paused new patient enrollment, but Biohaven remains optimistic about the ongoing dosing for enrolled patients. The company is expected to provide further updates on the status of the clinical trials and the implications of the FDA's decision.